Free Trial

Evoke Pharma Q4 2022 Earnings Report

Evoke Pharma logo
$4.46 +0.06 (+1.36%)
As of 03:46 PM Eastern

Evoke Pharma EPS Results

Actual EPS
-$6.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
$0.80 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Slide Deck

Evoke Pharma Earnings Headlines

StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)
Evoke underscores committment to patients after FDA update on domperidone
2025: Crypto Opportunities You Can’t Afford to Miss
Cryptocurrencies are once again gaining incredible momentum, and savvy investors are positioning themselves to capitalize on this surge in 2025. The question is—will you be among them? With groundbreaking advancements and increasing institutional adoption on the horizon, there's never been a better time to explore the potential gains in crypto. What’s Fueling the Crypto Comeback?
See More Evoke Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat